共 205 条
[1]
Slamon DJ(1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Sci 235 177-182
[2]
Clark GM(2000)Molecular portraits of human breast tumours Nature 406 747-752
[3]
Wong SG(2016)Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 17 367-377
[4]
Levin WJ(2017)Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer N Engl J Med 377 122-131
[5]
Ullrich A(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672
[6]
McGuire WL(2011)Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 1273-1283
[7]
Perou CM(2014)Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 J Clin Oncol 32 3744-3752
[8]
Sørlie T(2013)Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study Lancet Oncol 14 1121-1128
[9]
Eisen MB(2015)Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer N Engl J Med 372 134-141
[10]
van de Rijn M(2019)Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized Phase II Study J Clin Oncol 37 2610-2619